BG34-200

**BG34-200** is an oat bran-derived β-(1,3)-(1,4)-glucan carbohydrate molecule with an average molecular weight of ~200 kDa, developed by researchers at Case Western Reserve University as an immunotherapy for solid tumors. It binds multivalently and directly to the activated I-domain of CD11b (integrin alpha M, also known as CR3 or Mac-1) on tumor-associated myeloid cells, including inflammatory monocytes and macrophages, triggering endocytosis, F-actin cytoskeletal rearrangement, phagocytosis, ICAM-1 clustering, and differentiation into monocyte-derived dendritic cells. This reprograms the immunosuppressive tumor microenvironment to an immunogenic one, inducing pro-inflammatory cytokines (e.g., IFN-γ, TNF-α, CXCL9, CXCL10), enhancing IRF1 and PD-L1 expression, promoting CD4+ and CD8+ T-cell infiltration, and activating tumor-draining lymph node T cells specific for tumor antigens like gp100/PMEL. Intravenous administration demonstrates antitumor efficacy in preclinical mouse models of advanced melanoma (B16F10), osteosarcoma, and pancreatic ductal adenocarcinoma (PDAC), reducing tumor growth, metastases, and improving survival, with proposed phase 1/2 trials in pediatric/adolescent/young adult pulmonary metastatic osteosarcoma and veterinary trials in canine malignant melanoma.[1][5]